CN110964109B - 抗pd-l1抗体 - Google Patents

抗pd-l1抗体 Download PDF

Info

Publication number
CN110964109B
CN110964109B CN201911310366.8A CN201911310366A CN110964109B CN 110964109 B CN110964109 B CN 110964109B CN 201911310366 A CN201911310366 A CN 201911310366A CN 110964109 B CN110964109 B CN 110964109B
Authority
CN
China
Prior art keywords
ser
homology
antibody
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911310366.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110964109A (zh
Inventor
查济平
孙自勇
邱均专
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Crown Bioscience Inc Taicang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Crown Bioscience Inc Taicang filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN201911310366.8A priority Critical patent/CN110964109B/zh
Publication of CN110964109A publication Critical patent/CN110964109A/zh
Application granted granted Critical
Publication of CN110964109B publication Critical patent/CN110964109B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201911310366.8A 2014-08-05 2015-08-05 抗pd-l1抗体 Active CN110964109B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911310366.8A CN110964109B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014083715 2014-08-05
CNPCT/CN2014/083715 2014-08-05
CN201580042278.8A CN107001463B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体
PCT/US2015/043723 WO2016022630A1 (en) 2014-08-05 2015-08-05 Anti-pd-l1 antibodies
CN201911310366.8A CN110964109B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580042278.8A Division CN107001463B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体

Publications (2)

Publication Number Publication Date
CN110964109A CN110964109A (zh) 2020-04-07
CN110964109B true CN110964109B (zh) 2023-08-25

Family

ID=55264464

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201580042278.8A Active CN107001463B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体
CN201911310366.8A Active CN110964109B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体
CN201911310359.8A Active CN110964108B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体
CN202310833274.8A Pending CN118388646A (zh) 2014-08-05 2015-08-05 抗pd-l1抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201580042278.8A Active CN107001463B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201911310359.8A Active CN110964108B (zh) 2014-08-05 2015-08-05 抗pd-l1抗体
CN202310833274.8A Pending CN118388646A (zh) 2014-08-05 2015-08-05 抗pd-l1抗体

Country Status (15)

Country Link
US (3) US10435470B2 (enExample)
EP (1) EP3177649B1 (enExample)
JP (2) JP6909153B2 (enExample)
KR (1) KR102476226B1 (enExample)
CN (4) CN107001463B (enExample)
AU (2) AU2015301126B2 (enExample)
CA (1) CA2956399A1 (enExample)
ES (1) ES2987034T3 (enExample)
IL (1) IL250415B (enExample)
MX (2) MX390385B (enExample)
NZ (1) NZ728749A (enExample)
RU (1) RU2722212C9 (enExample)
SG (2) SG10201901057UA (enExample)
WO (1) WO2016022630A1 (enExample)
ZA (1) ZA201700785B (enExample)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CA2955788C (en) 2014-07-22 2024-01-16 Ziyong Sun Anti-pd-1 antibodies
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
SMT202100527T1 (it) 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CN115850521A (zh) 2016-02-05 2023-03-28 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
CA3021669A1 (en) * 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
CN106008714B (zh) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
US10077308B2 (en) 2016-06-13 2018-09-18 Askgene Pharma Inc. PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
CN109689688B (zh) 2016-08-09 2023-06-13 科马布有限公司 抗icos抗体
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN108203720A (zh) * 2016-12-20 2018-06-26 上海生博生物医药科技有限公司 能靶向Her2并封闭PD-L1降低肿瘤免疫逃逸的CAR-T载体及其构建方法和应用
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
CN108456251A (zh) * 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
CN107164410B (zh) * 2017-05-27 2019-09-03 上海优卡迪生物医药科技有限公司 一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
CN107299110B (zh) * 2017-05-27 2019-11-22 上海优卡迪生物医药科技有限公司 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US12150990B2 (en) 2017-11-02 2024-11-26 Nanjing Shunxin Pharmaceutical Co., Ltd. Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
KR102311838B1 (ko) * 2017-12-27 2021-10-14 주식회사 파멥신 항-pd-l1 항체 및 이의 용도
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
SG11202005273XA (en) * 2017-12-28 2020-07-29 Nanjing Legend Biotech Co Ltd Antibodies and variants thereof against pd-l1
US11359021B2 (en) * 2018-01-10 2022-06-14 Jiangsu Hengrui Medicine Co., Ltd. PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CA3091373A1 (en) * 2018-02-17 2019-08-22 Apollomics Inc. Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
CN111954682A (zh) * 2018-03-19 2020-11-17 阿贝奥姆公司 针对程序性死亡配体1(pd-l1)的高亲和力中和单克隆抗体及其用途
AU2018418224B2 (en) * 2018-04-09 2025-04-17 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
WO2020041404A1 (en) * 2018-08-23 2020-02-27 Macrogenics, Inc. Pd-l1-binding molecules and use of the same for the treatment of disease
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
PT3880186T (pt) 2018-11-14 2024-05-28 Regeneron Pharma Administração intralesional de inibidores de pd-1 para o tratamento do cancro de pele
WO2020135415A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
JP2022516072A (ja) * 2018-12-27 2022-02-24 ギガジェン，インコーポレイティッド 抗ｐｄ－ｌ１結合タンパク質およびその使用方法
CN118267468A (zh) * 2019-01-25 2024-07-02 正大天晴药业集团股份有限公司 治疗肿瘤的联用药物组合物
WO2020156500A1 (zh) * 2019-01-31 2020-08-06 正大天晴药业集团股份有限公司 抗pd-l1抗体治疗头颈癌的用途
JP2022521800A (ja) 2019-02-28 2022-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 皮膚がんを治療するためのｐｄ－１阻害剤の投与
MX2021010560A (es) 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
CA3133141A1 (en) * 2019-03-15 2020-09-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating small cell lung cancer
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
CN111973739B (zh) * 2019-05-23 2024-02-13 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
CN113939315B (zh) * 2019-05-30 2024-04-02 正大天晴药业集团南京顺欣制药有限公司 治疗黑色素瘤的联用药物组合物
CN113905761A (zh) * 2019-06-10 2022-01-07 正大天晴药业集团南京顺欣制药有限公司 治疗驱动基因阳性肺癌的联用药物组合物
EP3980067A4 (en) * 2019-06-10 2023-08-02 Apollomics Inc. (Hangzhou) ANTIBODY INTERLEUKIN FUSION PROTEIN AND METHODS OF USE
CN112168961A (zh) * 2019-07-03 2021-01-05 正大天晴药业集团南京顺欣制药有限公司 治疗结直肠癌的联用药物组合物
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP4023679A4 (en) * 2019-08-30 2023-10-04 Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group FUSION PROTEIN TARGETING PD-L1 AND TGF-BETA AND USE THEREOF
CN113039208B (zh) * 2019-09-30 2022-11-04 和铂医药(上海)有限责任公司 一种抗pd-l1抗原结合蛋白及其应用
US20230002492A1 (en) * 2019-11-08 2023-01-05 Simcere (Shanghai) Pharmaceutical Co., Ltd. Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
IL272389A (en) * 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
CN113318226A (zh) * 2020-02-28 2021-08-31 正大天晴药业集团股份有限公司 抗pd-l1抗体联合放射性射线治疗肺癌的方法
KR20220163991A (ko) 2020-04-02 2022-12-12 치아타이 티안큉 파마수티컬 그룹 주식회사 Cd47에 결합하는 항원-결합 폴리펩타이드 및 이의 용도
CA3181598A1 (en) * 2020-04-30 2021-11-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination drug for treating kidney cancer
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
MX2022014734A (es) 2020-05-26 2023-03-15 Regeneron Pharma Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
WO2021244551A1 (zh) 2020-06-02 2021-12-09 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物
AU2021301947A1 (en) * 2020-06-30 2023-02-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug for treating tumor
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
WO2022033585A1 (zh) 2020-08-13 2022-02-17 正大天晴药业集团股份有限公司 用于治疗软组织肉瘤的联用药物
JP2023540217A (ja) 2020-08-26 2023-09-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することによりがんを処置する方法
MX2023002650A (es) 2020-09-03 2023-06-08 Regeneron Pharma Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1.
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
EP4303231A4 (en) 2021-02-07 2025-02-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BISPECIFIC ANTIBODY
AU2022242000A1 (en) 2021-03-23 2023-09-14 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
EP4316518A4 (en) 2021-03-29 2025-03-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combination of toll-like receptor 7 agonist and anti-pd-l1 antibody
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
KR20240038991A (ko) 2021-07-19 2024-03-26 리제너론 파마슈티칼스 인코포레이티드 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합
US20240316031A1 (en) 2021-07-22 2024-09-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination drug for treatment of gastric carcinoma and/or esophagogastric junction cancer
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
JP2024527974A (ja) * 2021-08-05 2024-07-26 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 小細胞肺がんを治療する薬物の組み合わせ
WO2023030532A1 (zh) * 2021-09-06 2023-03-09 正大天晴药业集团股份有限公司 用于治疗食管癌的药物组合
MX2024003025A (es) 2021-09-16 2024-03-26 Chia Tai Tianqing Pharmaceutical Group Co Ltd Conjugado de anticuerpo anti-her3-farmaco, composicion de este y uso de este.
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
US20240269278A1 (en) 2021-09-30 2024-08-15 Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group Anti-cd47 antibody for combined treatment of blood tumor
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023098798A1 (zh) 2021-12-01 2023-06-08 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的药物组合
IL314851A (en) 2022-02-17 2024-10-01 Regeneron Pharma Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
WO2023174408A1 (zh) * 2022-03-18 2023-09-21 正大天晴药业集团南京顺欣制药有限公司 抗tim-3抗体与抗pd-l1抗体的药物组合
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
CN119278053A (zh) * 2022-06-02 2025-01-07 正大天晴药业集团股份有限公司 用于治疗子宫恶性肿瘤的药物组合
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025080538A1 (en) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
CN117783521B (zh) * 2023-11-23 2025-03-04 中国农业科学院兰州兽医研究所 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
CN102245640A (zh) * 2008-12-09 2011-11-16 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CN105579471A (zh) * 2012-12-21 2016-05-11 默沙东公司 结合人程序性死亡配体1(pd-l1)的抗体

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60033293D1 (de) 1999-08-23 2007-03-22 Dana Farber Cancer Inst Inc Neue b7-4 moleküle und deren verwendungen
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
CN1423700A (zh) 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
WO2001079299A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
AU2002224037A1 (en) 2000-11-15 2002-05-27 Tasuku Honjo Pd-1-lacking mouse and use thereof
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CN1296385C (zh) 2005-03-30 2007-01-24 王哲 抗猪生长激素单克隆抗体及制备方法及应用
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
KR20080074220A (ko) 2005-12-08 2008-08-12 밀레니엄 파머슈티컬스 인코퍼레이티드 키나아제 억제 활성을 갖는 비시클릭 화합물
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
WO2007136572A2 (en) 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
SG173364A1 (en) * 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
AU2014201367B2 (en) 2007-06-18 2016-01-28 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US9243052B2 (en) 2007-08-17 2016-01-26 Daniel Olive Method for treating and diagnosing hematologic malignancies
ES2636460T3 (es) * 2007-10-08 2017-10-05 Intrexon Corporation Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer
UA105760C2 (uk) * 2007-10-16 2014-06-25 Ес-Бі-Ай Біотех Ко., Лтд. Антитіло проти bst2
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
AU2013204861B2 (en) * 2008-09-26 2016-05-12 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
KR101721707B1 (ko) 2008-11-28 2017-03-30 에모리 유니버시티 감염 및 종양 치료 방법
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
WO2010089411A2 (en) * 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
NZ594985A (en) 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011056644A2 (en) 2009-10-28 2011-05-12 Centocor Ortho Biotech Inc. Anti-glp-1r antibodies and their uses
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
LT2536745T (lt) 2010-02-19 2016-09-26 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
RU2563346C2 (ru) 2011-03-31 2015-09-20 Мерк Шарп И Доум Корп. Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
MX2013012785A (es) 2011-05-02 2014-05-28 Ym Biosciences Australia Pty Tratamiento del mieloma multiple.
RU2616881C2 (ru) 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
CN102836441B (zh) * 2011-06-24 2019-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
AU2012290121B2 (en) 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CA2873402C (en) * 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
KR102129636B1 (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
HK1208810A1 (en) 2012-07-03 2016-03-18 Janssen Alzheimer Immunotherapy C-terminal and central epitope a-beta antibodies
WO2014022758A1 (en) * 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
KR101947702B1 (ko) * 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
CA2889182A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP2934577A1 (en) 2012-12-19 2015-10-28 Adimab, LLC Multivalent antibody analogs, and methods of their preparation and use
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
ES2678221T3 (es) 2013-02-20 2018-08-09 Regeneron Pharmaceuticals, Inc. Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas
CA2904377C (en) 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CA2955788C (en) 2014-07-22 2024-01-16 Ziyong Sun Anti-pd-1 antibodies
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
CN102245640A (zh) * 2008-12-09 2011-11-16 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CN105579471A (zh) * 2012-12-21 2016-05-11 默沙东公司 结合人程序性死亡配体1(pd-l1)的抗体

Also Published As

Publication number Publication date
KR20170039706A (ko) 2017-04-11
AU2015301126A1 (en) 2017-02-23
EP3177649A4 (en) 2018-04-25
MX2017001597A (es) 2017-11-17
CA2956399A1 (en) 2016-02-11
JP7144477B2 (ja) 2022-09-29
CN107001463A (zh) 2017-08-01
WO2016022630A1 (en) 2016-02-11
CN110964108B (zh) 2023-07-07
CN118388646A (zh) 2024-07-26
MX2022002364A (es) 2022-04-06
MX390385B (es) 2025-03-20
SG11201700687TA (en) 2017-02-27
EP3177649A1 (en) 2017-06-14
KR102476226B1 (ko) 2022-12-12
IL250415A0 (en) 2017-03-30
EP3177649B1 (en) 2024-02-28
US11111300B2 (en) 2021-09-07
RU2722212C2 (ru) 2020-05-28
AU2015301126B2 (en) 2021-03-11
AU2021203593B2 (en) 2024-04-18
US20210371531A1 (en) 2021-12-02
NZ728749A (en) 2023-06-30
BR112017002234A2 (pt) 2018-07-24
CN110964109A (zh) 2020-04-07
NZ766660A (en) 2024-02-23
CN107001463B (zh) 2020-01-17
JP6909153B2 (ja) 2021-07-28
SG10201901057UA (en) 2019-03-28
JP2017523786A (ja) 2017-08-24
CN110964108A (zh) 2020-04-07
US10435470B2 (en) 2019-10-08
RU2017106804A3 (enExample) 2019-08-27
ES2987034T3 (es) 2024-11-13
RU2017106804A (ru) 2018-09-06
ZA201700785B (en) 2021-07-28
US20200031935A1 (en) 2020-01-30
AU2021203593A1 (en) 2021-07-01
IL250415B (en) 2020-09-30
US11827707B2 (en) 2023-11-28
US20170204184A1 (en) 2017-07-20
RU2722212C9 (ru) 2020-07-23
JP2020141672A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
AU2021203593B2 (en) Anti-pd-l1 antibodies
AU2021200264B2 (en) Anti-pd-1 antibodies
CN108779175B (zh) NKp46结合蛋白的可变区
CN110023338A (zh) 用于与抗pd-l1抗体组合的抗tim-3抗体
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
CN114685657A (zh) 一种功能增强型抗体阻断剂的开发及其应用
CN114008077A (zh) 抗体和使用方法
HK40025947A (en) Anti-pd-l1 antibodies
HK40025946A (en) Anti-pd-l1 antibodies
HK40025947B (zh) 抗pd-l1抗体
CN112079924B (zh) Pd-l1靶向结合剂及其用途
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
BR122020026802B1 (pt) Anticorpo isolado que se liga a pd-l1 ou fragmento do mesmo, uso do anticorpo ou fragmento, composição, polinucleotídeo isolado e vetor de expressão
BR112017002234B1 (pt) Anticorpo isolado que se liga a pd-l1 ou fragmento do mesmo, uso do anticorpo ou fragmento, composição, polinucleotídeo isolado e vetor de expressão

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025947

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant